15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry dataR Baldassano, Harland S. Winter, Anne M. Griffiths et al.|Journal of Crohn s and Colitis|2013Cited by 3
P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry dataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Journal of Crohn s and Colitis|2013Cited by 3
Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryM Dubinsky, Meena Thayu, Jeffrey Hyams et al.|Journal of Crohns & Colitis|2016Cited by 0
REDUCTION IN FISTULA IN INFLIXIMAB TREATED PATIENTSWallace Crandall, Robert N. Baldassano, Jeffrey Hyams et al.|Journal of Pediatric Gastroenterology and Nutrition|2006Cited by 0